5.6.4. pharmacological management. 5.6.4.1. drugs urgency urinary incontinence muscarinic receptor antagonists [654-657] beta-3 agonist [308-310,658-661] currently first-line pharmacological treatments uui. mechanism action, efficacy, safety tolerability profiles classes drugs discussed detail sections 5.2.3 5.2.4, respectively. 5.6.4.2. drugs stress urinary incontinence sr eight studies evaluating efficacy duloxetine postprostatectomy sui reported duloxetine resulted mean dry rate 58% (25–89%), mean improvement pad number 61% (12–100%), mean improvement one-hour pad weight 68% (53–90%), short-term follow-up (mean one nine months) . however, mean adverse event rates high, treatment discontinued 38% cases. common adverse events included: fatigue, somnolence nausea reported 18% patients . overall certainty evidence low due study heterogeneity methodological limitations. rcts long-term follow-up required. duloxetine currently prescribed off-label setting. summary evidenceleantimuscarinic monotherapy significantly improve urgency, uui, increased daytime frequency.1bmirabegron superior placebo efficacious antimuscarinics improvement uui.1bduloxetine led short-term improvement post-prostatectomy sui symptoms qol improvement; however, significant proportion men discontinued treatment.1b recommendationsstrength ratingoffer antimuscarinic drugs mirabegron adults urgency urinary incontinence failed conservative treatment.strongoffer duloxetine men stress urinary incontinence.weakinform patients possible adverse events duloxetine use label indication europe.strong